Navigation Links
Professor Doug Hilton wins Milstein Award for cytokine research
Date:10/8/2011

Medical researcher and director of the Walter and Eliza Hall Institute, Professor Doug Hilton, has become the first Australian recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research.

Professor Hilton will be presented with the award today in Florence, Italy, at the 9th Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research.

Cytokines are chemicals that transmit messages between cells, particularly in the immune system. Interferons are a subset of cytokines that enhance immune responses to viruses and other pathogens, and can be used to treat cancers.

The Milstein Award was established in 1988 by American philanthropists Seymour and Vivian Milstein to recognise scientists who have made exceptional contributions to cytokine and interferon research. The late Mr Milstein was a New York real estate magnate who was a strong supporter of medical research and patient care organisations. The Milsteins were inspired to establish the award in 1988 by the emerging medical applications of interferons.

Professor Hilton's receipt of the award recognises his research into how cytokines signal between cells, including the discovery of many molecules involved in this process.

Professor Hilton said he was deeply honoured to receive the 2011 Milstein Award. "I have worked in the field of cytokine biology since the 1980s," Professor Hilton said. "In the past two decades we have seen many new treatments for cancer, infectious diseases and autoimmune conditions evolve from laboratory discoveries about basic cytokine biology."

After completing his undergraduate studies at Monash University, Professor Hilton undertook research training with Professors Don Metcalf and Nick Nicola at the Walter and Eliza Hall Institute. During this period he discovered the cytokine Leukaemia Inhibitory Factor (LIF), which is now under investigation for its role in conditions including infertility and cancer. Professor Hilton subsequently investigated the cytokine erythropoietin at the Whitehead Institute, United States.

Since 1993, Professor Hilton has continued his research at the Walter and Eliza Hall Institute. He and his research team have discovered cellular receptors for two cytokines, interleukin-11 and interleukin-13, as well as the Suppressors of Cytokine Signalling (SOCS) family of proteins, which may be important in viral infections and the development of cancer.

Professor Hilton now heads the institute's Molecular Medicine division, where he leads a research group studying the molecules important for blood production. His scientific achievements have attracted numerous honours including the Australian Academy of Science's Gottschalk Medal, the Australian Institute of Political Science's "Tall Poppy" Award and the Commonwealth Health Minister's Award for Excellence in Health and Medical Research. He was named one of Australia's "Top 10 Scientific Minds Under 45" by Cosmos magazine in 2006, and one of The Age's "Top 100 People" in 2009.

Professor Hilton became the sixth director of the Walter and Eliza Hall Institute in July 2009. He has been a passionate advocate for medical research, and in 2011 initiated the 'Discoveries Need Dollars: Protect Medical Research' campaign, which brought the community together in support of maintenance of the Australian government's medical research funding budget.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. National Science Foundation grants Clemson professors award to develop nanoprobes
2. University professor stresses links between US Navy sonar and whale strandings
3. Minnesota ecology professor wins international award for biodiversity and biofuels research
4. NJIT professors research suggests changes in underwater data communications
5. 2 Alexander von Humboldt professorships go to LMU Munich
6. Top biophysics award to Professor Ray Norton
7. University of Leicester professor adds new perspective to rainforest debate
8. NJIT professor finds engineering technique to identify disease-causing genes
9. Chemistry professor 1 of only 3 at UH to achieve prestigious AAAS status
10. Florida professor creates endowment for insect scientists
11. Dinner, lecture series to honor legacy of distinguished UH professor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Professor Doug Hilton wins Milstein Award for cytokine research
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: